Psychedelics: the next trip for CMOs
Physicians hope increasing approvals of psychedelics will help reduce opioid prescriptions to combat the addiction epidemic.
By
Comment
Latest in
Comment
NICE Updates UK Guidelines for Lokelma in CKD-HK
The National Institute of Health and Care Excellence (NICE) has updated its guideline for AstraZeneca’s Lokelma (sodium zirconium cyclosilicate) in…
By
Virtual Care and Telemedicine: Healthcare and medical device trends
The virtual care space includes a rich ecosystem of players across the telehealth and remote patient monitoring segments. Telehealth is…
Antibacterial resistance needs a global-scale response like Covid-19
On January 19, The Lancet published the paper 'Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis'. This…
By
The Epstein-Barr virus could be the leading cause of multiple sclerosis
A recent study revealed that the EBV virus is the likely cause of MS, although further studies are needed to…
By
Macro view: Covid stimulus drives rapid inflation in US
Macro view: A majority of economists believe that stimulus-spurred consumer buying is a big part of the reason US inflation…
KRAS G12C inhibitors in NSCLC forecast to achieve over $1bn in sales by 2024
GlobalData estimates that Amgen’s Lumakras (sotorasib) is set to become a blockbuster agent in non-small cell lung cancer.
By
Macro view: Omicron to affect GDP growth if restrictions ease
Some economists believe that as holiday demand and supply chain woes ease, the situation should improve in 2022 but Omicron…